Drug profile · INN
eszopiclone
LUNIVIA
eszopiclone (LUNIVIA) is a gaba-a receptor; anion channel positive allosteric modulator. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — eszopiclone
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 2
- Data quality
- 0.89
Quick answer
eszopiclone (LUNIVIA) is a gaba-a receptor; anion channel positive allosteric modulator. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
GABA-A receptor; anion channel positive allosteric modulator
Primary target: GABA-A receptor; anion channel
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | application withdrawn | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is eszopiclone?
eszopiclone (LUNIVIA) is a gaba-a receptor; anion channel positive allosteric modulator. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for eszopiclone?
LUNIVIA is a marketed brand name for eszopiclone. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of eszopiclone?
eszopiclone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.